THERAPY DOSSIER · th-a3aadf584aa0

Inducible nitric oxide synthase antisense oligonucleotides (iNOS ASOs)

Other · Antisense oligonucleotide (iNOS ASO); not a ChEMBL entity, preclinical

Evidence & regulatory context

Mechanism: Antisense oligonucleotide (iNOS ASO); not a ChEMBL entity, preclinical
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22708918 ↗2012Mixed findings

Acute molecular perturbation of inducible nitric oxide synthase with an antisense approach enhances neuronal preservation and functional recovery after contusive spinal cord injury.

RatSpinal cord injuryContusionF344 (Fischer 344)Femalen = n=10 per group, three groupsSpinal superfusion200 nM3 h after injury

Model: Moderate contusive spinal cord injury at thoracic T8

No significant difference in BBB score against controls, but BBB subscore analysis showed significant improvement in foot positioning, trunk stability and tail clearance. No gross improvement in preserved white or grey matter, though greater numbers of surviving neurons were present adjacent to the…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…